Last edition
News about "Antibody-Drug Conjugates Development"
Cohance Lifesciences Advances its ADC Strategy Investment of USD 18 million in NJ Bio and Aruka Bio
Cohance Lifesciences invests USD 18 million in NJ Bio and Aruka Bio to strengthen its ADC strategy, customer services and proprietary pipeline development.
Antibody Drug Conjugates Development | 04/09/2026 | By News Bureau
With this new capability, Syngene will offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs) – from discovery through to GMP manufacturing – placing it among a handful of CDMOs with full-service capabilities.
Antibody-Drug Conjugates Development | 24/10/2025 | By Darshana | 273
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy